You're visiting from outside the EU. Switch to the US version to see local pricing and tax details in USD.

Switch to US ($)
Contact +33 (0)3 90 20 54 70

  • Verbesserung der Antikörper-Developierbarkeit

    Oumayma Rouis Oumayma Rouis 6 min read

    Haben Sie einen therapeutischen Antikörperkandidaten mit suboptimalen Herstellungseigenschaften wie geringer Ausbeute, hoher Aggregation oder Schwierigkeiten bei der Aufreinigung? Unser engagiertes Team von Antikörper-Experten nutzt 25 Jahre Erfahrung…

  1. How the environment shapes immune system development during pregnancy

    Read more

  2. Which approach should you choose to get a species-specific veterinary monoclonal antibody? A decision guide

    Read more

  3. Gene Integration in Antibody Production: Overcoming Challenges for Optimal Clone Selection

    Read more

  4. A Guide to Choosing the Right CRO for Transient Recombinant Antibody Production

    Read more

  5. Humanized vs. Fully Human Antibodies: What’s the Difference?

    Read more

Cart (0 Items)

Your cart is currently empty.

View Products